Mannatech Inc

Mannatech Inc (MTEX) Stock Analysis

$8.110

+0.050 (+0.62%)At close

Loading chart…
High
8.640
Open
8.290
VWAP
8.17
Volume
10.84K
Mkt Cap
13.10M
Low
7.770
Amount
88.58K
EV/EBITDA, TTM
0.00

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies.

AI analysis of Mannatech Inc (MTEX)

Hold

Mannatech Inc is not a strong buy right now due to its current price of $8.11, which is significantly below its 52-week high of $9.97. The RSI of 41.05 indicates the stock is nearing oversold territory, but the recent 5-day change of -4.25% suggests downward momentum. The upcoming earnings report on November 11 could provide more clarity on its financial health, but the company has faced declining revenues, with a 6.2% year-over-year decrease reported for Q1 2026.

Valuation Metrics

The current forward P/E ratio for Mannatech Inc (MTEX) is 9.57, compared to its 5-year average forward P/E of 1.70.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.70
Current P/E
9.57
Overvalued
5.22
Undervalued
-1.83

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for MTEX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MTEX

$9.48

Scenario price

B

Base

Base · 50%MTEX

$7.93

Scenario price

B

Bear

Bear · 25%MTEX

$7.87

Scenario price

Events Timeline

2026-09-24 (ET)

10:00:00

Mannatech Trading Halted Due to Volatility

2026-09-01 (ET)

16:30:00

Mannatech Board Chairman Change Announced

2026-08-14 (ET)

14:30:00

Mannatech Trading Resumes

14:30:00

Mannatech Trading Halted Due to Volatility

2026-04-07 (ET)

16:00:00

Mannatech Trading Halted Due to Volatility

News

MTEX FAQ — answered by Alphio AI

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Mannatech Inc is not a strong buy right now due to its current price of $8.11, which is significantly below its 52-week high of $9.97. The RSI of 41.05 indicates the stock is nearing oversold territory, but the recent 5-day change of -4.25% suggests downward momentum. The upcoming earnings report on November 11 could provide more clarity on its financial health, but the company has faced declining revenues, with a 6.2% year-over-year decrease reported for Q1 2026.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading